Avenue Therapeutics reports FY2022 net loss of $3.6M; cash $6.7M; pipeline updates

AVENUE THERAPEUTICS, INC.

Net loss $3.6M ($1.63/share) vs $3.7M ($3.29/share) in 2021; R&D $2.7M, G&A $5.3M.
Cash $6.7M at Dec 31, 2022, up from $3.8M; raised $12M in Oct 2022 offering and $3.25M in Jan 2023.
In-licensed AJ201 for SBMA (Kennedy's Disease) in Phase 1b/2a; FDA granted Orphan Drug Designation.
IV Tramadol: Type C meeting with FDA in March 2023; update expected in April 2023.
Completed acquisition of Baergic Bio in Nov 2022; appointed Alexandra MacLean to board.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AVENUE THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share, EPS $1.63 per share.

Period: the full year ended December 31, 2022
Net income: Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share
EPS: $1.63 per share
Result: reported results

Exact text from the filing

Avenue Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-039135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.